Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Novarits

- PMLiVE

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Around 60% of chronic spontaneous urticaria patients are uncontrolled by H1-antihistamines

- PMLiVE

Novartis reveals positive efficacy data for Xolair follow-up

Next-generation treatment is more effective than current therapy

Novartis plans digital therapeutics for schizophrenia and MS

Will work with Pear Therapeutics on a prescription software range

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

Novartis building

Novartis’ omalizumab effective in chronic skin disease

Study backs extended use of asthma treatment Xolair

Novartis building

Novartis’ omalizumab on track for filing in serious skin disease

Is active ingredient in asthma drug Xolair

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links